Skip to main content
SpringerLink
Log in

Variant Histology: Management Pearls

  • Chapter
  • First Online:
Bladder Cancer

Abstract

Variant histology in the urothelial tract encompasses variants of urothelial carcinoma as well as non-urothelial tumors seen in varying proportions. Though universally designated as aggressive in the beginning, gradual understanding of the biology and clinical behavior has led to better categorization of these tumors. Most variant tumors present at an advanced stage but, apart from certain subtypes, share similar stage matched clinical characteristics to conventional urothelial carcinoma. In non-urothelial variants like the small-cell neuroendocrine cancer, upfront chemotherapy has an established role with distinct survival advantage whereas optimal management of the micropapillary variant is controversial. Notwithstanding these facts, radical cystectomy is the principal management approach for most invasive, variant histology bladder tumors. Our current knowledge of these uncommon tumors is based mostly on retrospective analyses. Growing knowledge of molecular heterogeneity along with improvements in multimodal approaches will further enhance our management of these tumors.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 249.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Humphrey PA, Moch H, Cubilla AL, Ulbright TM, Reuter VE, Catto J. Platinum priority – guidelines the 2016 WHO classification of tumours of the urinary system and male genital organs — part B : prostate and bladder tumours. Eur Urol. 2016;70:106–19.

    Article  PubMed  Google Scholar 

  2. Alanee S, Alvarado I, Murugan P, Rajeev M, Kenneth K. Update of the international consultation on urological diseases on bladder cancer 2018 : non – urothelial cancers of the urinary bladder. World J Urol. 2018. https://doi.org/10.1007/s00345-018-2421-5.

  3. Moschini M, Andrea DD, Korn S, Irmak Y, Soria F, Compérat E, Shariat SF. Characteristics and clinical significance of histological variants of bladder cancer. Nat Rev Urol. 2017;14:651–68.

    Article  PubMed  Google Scholar 

  4. Moschini M, Shariat SF, Lucianò R, et al. Pure but not mixed histologic variants are associated with poor survival at radical cystectomy in bladder cancer patients. Clin Genitourin Cancer. 2017;15:e603–7.

    Article  PubMed  Google Scholar 

  5. Wasco MJ, Daignault S, Zhang Y, Kunju LP, Kinnaman M, Braun T, Lee CT, Shah RB. Urothelial carcinoma with divergent histologic differentiation (mixed histologic features) predicts the presence of locally advanced bladder cancer when detected at transurethral resection. Urology. 2007;70:69–74.

    Article  PubMed  Google Scholar 

  6. Hansel DE, Amin MB, Comperat E, Cote RJ, Knu R, Montironi R, Reuter VE, Soloway MS, Umar SA, Van Der Kwast TH. Collaborative review – bladder cancer a contemporary update on pathology standards for bladder cancer : transurethral resection and radical cystectomy specimens. Eur Urol. 2013;63:321–32.

    Article  PubMed  Google Scholar 

  7. Abd A, Watts KE, Elson P, Fergany A, Hansel DE. The sensitivity of initial transurethral resection or biopsy of bladder tumor ( s ) for detecting bladder cancer variants on radical cystectomy. J Urol. 2013;189:1263–7.

    Article  Google Scholar 

  8. Willis D, Kamat AM. Nonurothelial bladder cancer and rare variant Histologies. Hematol Clin NA. 2015;29:237–52.

    Article  Google Scholar 

  9. Shah RB, Montgomery JS, Montie JE, Kunju LP. Variant ( divergent ) histologic differentiation in urothelial carcinoma is under-recognized in community practice : impact of mandatory central pathology review at a large referral hospital. Urol Oncol. 2013;31:1650–5.

    Article  PubMed  Google Scholar 

  10. Luchey AM, Manimala NJ, Dickinson S, et al. Change in management based on pathologic second opinion among bladder cancer patients presenting to a comprehensive cancer center: implications for clinical practice. Urology. 2016;93:130–4.

    Article  PubMed  Google Scholar 

  11. Gordetsky J, Collingwood R, Lai WS, Del M, Rodriquez C, Rais-bahrami S. Second opinion expert pathology review in bladder cancer : implications for patient care. Int J Surg Pathol. 2018;26:12–7.

    Article  PubMed  Google Scholar 

  12. Abufaraj M, Shariat SF, Foerster B, Susani M, Czech AK, Karakiewicz PI, Seebacher V. Accuracy and prognostic value of variant histology and lymphovascular invasion at transurethral resection of bladder. World J Urol. 2018;36:231–40.

    Article  PubMed  Google Scholar 

  13. Lopez-Beltran A, Henriques V, Montironi R, Cimadamore A, Raspollini MR, Cheng L. Variants and new entities of bladder cancer. Histopathology. 2019;74:77–96.

    Article  PubMed  Google Scholar 

  14. Shanks JH, Iczkowski KA. Divergent differentiation in urothelial carcinoma and other bladder cancer subtypes with selected mimics. Histopathology. 2009;54:885–900.

    Article  CAS  PubMed  Google Scholar 

  15. Kim SP, Frank I, Cheville JC, Thompson RH, Weight CJ, Thapa P, Boorjian SA. The impact of squamous and glandular differentiation on survival after radical cystectomy for urothelial carcinoma. J Urol. 2012;188:405–9.

    Article  PubMed  Google Scholar 

  16. Li G, Hu J, Niu Y. Squamous differentiation in pT1 bladder urothelial carcinoma predicts poor response for intravesical chemotherapy. Oncotarget. 2018;9:217–23.

    Article  CAS  PubMed  Google Scholar 

  17. Liu Y, Bui MM, Xu B. Urothelial carcinoma with squamous differentiation is associated with high tumor stage and pelvic lymph-node metastasis. Cancer Control. 2017;24:78–82.

    Article  PubMed  Google Scholar 

  18. Mitra AP, Bartsch CC, Bartsch G Jr, Miranda G, Skinner EC, Daneshmand S. Does presence of squamous and glandular differentiation in urothelial carcinoma of the bladder at cystectomy portend poor prognosis ? An intensive case-control analysis. Urol Oncol Semin Orig Investig. 2014;32:117–27.

    Google Scholar 

  19. Lim M, Adsay NV, Grignon D, Osunkoya AO. Urothelial carcinoma with villoglandular differentiation: a study of 14 cases. Mod Pathol. 2009;22:1280–6.

    Article  PubMed  Google Scholar 

  20. Yang Z, Epstein JI. Urothelial carcinoma in situ of the bladder with glandular differentiation. Am J Surg Pathol. 2018;42:971–6.

    Article  PubMed  Google Scholar 

  21. Douglas J, Sharp A, Chau C, Head J, Drake T, Wheater M, Geldart T, Mead G, Crabb SJ. Serum total hCGβ level is an independent prognostic factor in transitional cell carcinoma of the urothelial tract. Br J Cancer. 2014;110:1759–66.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Murphy WMDD. The nested variant of transitional cell carcinoma: a neoplasm resembling proliferation of Brunn’s nests. Mod Pathol. 1992;5:240–3.

    CAS  PubMed  Google Scholar 

  23. Williamson SR, Zhang S, Lopez-Beltran A, Shah RB, Montironi R, Tan PH, Wang M, Baldridge LA, MacLennan GT, Cheng L. Lymphoepithelioma-like carcinoma of the urinary bladder: Clinicopathologic, immunohistochemical, and molecular features. Am J Surg Pathol. 2011;35:474–83.

    Article  PubMed  Google Scholar 

  24. Martin JE, Jenkins BJ, Zuk RJ, Oliver RTD, Baithun SI. Human chorionic gonadotrophin expression and histological findings as predictors of response to radiotherapy in carcinoma of the bladder. Virchows Arch A Pathol Anat Histopathol. 1989;414:273–7.

    Article  CAS  PubMed  Google Scholar 

  25. Tamas EF, Nielsen ME, Schoenberg MP, Epstein JI. Lymphoepithelioma-like carcinoma of the urinary tract: a clinicopathological study of 30 pure and mixed cases. Mod Pathol. 2007;20:828–34.

    Article  PubMed  Google Scholar 

  26. Keck B, Stoehr R, Wach S, et al. The plasmacytoid carcinoma of the bladder-rare variant of aggressive urothelial carcinoma. Int J Cancer. 2011;129:346–54.

    Article  CAS  PubMed  Google Scholar 

  27. Baldwin L, Lee AHS, Al-Talib RK, Theaker JM. Transitional cell carcinoma of the bladder mimicking lobular carcinoma of the breast: a discohesive variant of urothelial carcinoma. Histopathology. 2005;46:50–6.

    Article  CAS  PubMed  Google Scholar 

  28. Lopez-Beltran A, Blanca A, Montironi R, Cheng L, Regueiro JC. Pleomorphic giant cell carcinoma of the urinary bladder. Hum Pathol. 2009;40:1461–6.

    Article  CAS  PubMed  Google Scholar 

  29. Perepletchikov AM, Parwani AV. Micropapillary urothelial carcinoma: Clinico-pathologic review. Pathol Res Pract. 2009;205:807–10.

    Article  PubMed  Google Scholar 

  30. Zhai Q, Black J, Ayala A, Ro J. Histologic variants of infiltrating urothelial carcinoma. Arch Pathol Lab Med. 2007;131:1244–56.

    Article  PubMed  Google Scholar 

  31. Alvarado-Cabrero I, Sierra-Santiesteban FI, Alejandra Mantilla-Morales DM-H. Micropapillary carcinoma of the urothelial tract: a clinicopathologic study of 38 cases. Ann Diagn Pathol. 2005;9:1–5.

    Article  PubMed  Google Scholar 

  32. Kheiri B, Kanzy A, Krznarich T, Bachuwa G. Sarcomatoid urothelial carcinoma with disseminated metastases: an aggressive and rare cancer. BMJ Case Rep. 2017;2017:1–3.

    Google Scholar 

  33. Sanfrancesco J, McKenney JK, Leivo MZ, Gupta S, Elson P, Hansel DE. Sarcomatoid urothelial carcinoma of the bladder: analysis of 28 cases with emphasis on clinicopathologic features and markers of epithelial-to-mesenchymal transition. Arch Pathol Lab Med. 2016;140:543–51.

    Article  PubMed  Google Scholar 

  34. Lopez-Beltran A, Pacelli A, Rothenberg HJ, Wollan PC, Zincke H, Blute ML, Bostwick DG. Carcinosarcoma and sarcomatoid carcinoma of the bladder: Clinicopathological study of 41 cases. J Urol. 1998;159:1497–503.

    Article  CAS  PubMed  Google Scholar 

  35. Mai KT, Bateman J, Djordjevic B, Flood TA, Belanger EC. Clear cell urothelial carcinoma: a study of 10 cases and meta-analysis of the entity. Evidence of mesonephric differentiation. Int J Surg Pathol. 2017;25:18–25.

    Article  PubMed  Google Scholar 

  36. Leroy X, Gonzalez S, Zini L, Aubert S. Lipoid-cell variant of urothelial carcinoma: a clinicopathologic and immunohistochemical study of five cases. Am J Surg Pathol. 2007;31:770–3.

    Article  PubMed  Google Scholar 

  37. Park S, Reuter VE, Hansel DE. Non-urothelial carcinomas of the bladder. Histopathology. 2019;74:97–111.

    Article  PubMed  Google Scholar 

  38. Al-Ahmadie H, Iyer G. Updates on the genetics and molecular subtypes of urothelial carcinoma and select variants. Surg Pathol Clin. 2018;11:713–23.

    Article  PubMed  PubMed Central  Google Scholar 

  39. Robertson AG, Kim J, Al-Ahmadie H, et al. Comprehensive molecular characterization of muscle-invasive bladder cancer. Cell. 2017;171:540–556.e25.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  40. Tan TZ, Rouanne M, Tan KT, Huang RYJ, Thiery JP. Molecular subtypes of urothelial bladder cancer: results from a meta-cohort analysis of 2411 tumors. Eur Urol. 2018. https://doi.org/10.1016/j.eururo.2018.08.027.

  41. Sjödahl G, Eriksson P, Liedberg F, Höglund M. Molecular classification of urothelial carcinoma: global mRNA classification versus tumour-cell phenotype classification. J Pathol. 2017;242:113–25.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  42. Lindgren D, Frigyesi A, Gudjonsson S, et al. Combined gene expression and genomic profiling define two intrinsic molecular subtypes of urothelial carcinoma and gene signatures for molecular grading and outcome. Cancer Res. 2010;70:3463–72.

    Article  CAS  PubMed  Google Scholar 

  43. Warrick JI, Sjödahl G, Kaag M, Raman JD, Merrill S, Shuman L, Chen G, Walter V, DeGraff DJ. Intratumoral heterogeneity of bladder cancer by molecular subtypes and histologic variants. Eur Urol. 2018;5:23–4.

    Google Scholar 

  44. Shapur NK, Pode D, Shapiro A, Yutkin V, Pizov G, Apelbaum L, Zorn KC, Duvdevani M, Landau EH, Gofrit ON. Is radical cystectomy mandatory in every patient with variant histology of bladder cancer ? Rare Tumors. 2011;3:67–70.

    Article  Google Scholar 

  45. Porten SP, Willis D, Kamat AM. Variant histology : role in management and prognosis of nonmuscle invasive bladder cancer. Curr Opin Urol. 2014;24:517–23.

    Article  PubMed  Google Scholar 

  46. Yorozuya W, Nishiyama N, Shindo T, Kyoda Y, Itoh N, Sugita S, Hasegawa T. Cancer patients : retrospective multicenter study. Jpn J Clin Oncol. 2018;48:661–6.

    Article  PubMed  Google Scholar 

  47. Mally AD, Tin AL, Lee JK, Satasivam P, Cha EK, Donat SM, Herr HW, Bochner BH, Sjoberg DD, Dalbagni G. Clinical outcomes of patients with T1 nested variant of urothelial carcinoma compared to pure urothelial carcinoma of the bladder. Clin Genitourin Cancer. 2018;16:e23–7.

    Article  Google Scholar 

  48. Gofrit ON, Yutkin V, Shapiro A, Pizov G, Zorn KC, Di Francesco S. The response of variant histology bladder cancer to intravesical immunotherapy compared to conventional cancer. Front Oncol. 2016;6:1–5.

    Article  Google Scholar 

  49. Lynch SP, Shen Y, Kamat A, Grossman HB, Shah JB, Millikan RE, Dinney CP, Siefker-radtke A. Neoadjuvant chemotherapy in small cell urothelial cancer improves pathologic downstaging and long-term outcomes : results from a retrospective study at the MD Anderson Cancer Center. Eur Urol. 2013;64:307–13.

    Article  PubMed  Google Scholar 

  50. Cheng L, Pan C, Ph D, et al. Small cell carcinoma of the urinary bladder a clinicopathologic analysis of 64 patients. Cancer. 2004;101:957–62.

    Article  PubMed  Google Scholar 

  51. Li Q, Assel M, Benfante NE, Pietzak EJ, Herr HW, Donat M, Cha EK, Donahue TF, Bochner BH, Dalbagni G. The impact of plasmacytoid variant histology on the survival of patients with urothelial carcinoma of bladder after radical cystectomy. Eur Urol Focus. 2018. https://doi.org/10.1016/j.euf.2017.06.013.

  52. Kaimakliotis HZ, Monn MF, Cary KC, et al. Plasmacytoid variant urothelial bladder cancer : is it time to update the treatment paradigm ? Urol Oncol Semin Orig Investig. 2014;32:833–8.

    Google Scholar 

  53. Sui W, Matulay JT, Onyeji IC, Theofanides MC, James MB, Roychoudhury A, Wenske S, Decastro GJ. Contemporary treatment patterns and outcomes of sarcomatoid bladder cancer. World J Urol. 2017;35:1055–61.

    Article  CAS  PubMed  Google Scholar 

  54. Amin MB, Ro JY, El-Sharkawy T, Lee KM, Troncoso P, Silva EG, Ordonez NG, Ayala AG. Micropapillary variant of transitional cell carcinoma of the urinary bladder: histologic pattern resembling ovarian papillary serous carcinoma. Am J Surg Pathol. 1994;18:1224–32.

    Article  CAS  PubMed  Google Scholar 

  55. Kamat AM, Gee JR, Dinney CPN, Grossman HB, Swanson DA, Millikan RE, Detry MA, Robinson TL, Pisters LL. The case for early cystectomy in the treatment of. J Urol. 2006;175:881–5.

    Article  PubMed  Google Scholar 

  56. Spaliviero M, Dalbagni G, Bochner BH, et al. Clinical outcome of patients with T1 micropapillary urothelial carcinoma of the bladder. J Urol. 2014;192:702–7.

    Article  PubMed  PubMed Central  Google Scholar 

  57. Jackson BL, Mohammed A, Mayer N, Dormer JGT. Is immediate radical cystectomy necessary for all patients with non-muscle-invasive micropapillary bladder cancer? Urol Int. 2016;96:32–8.

    Article  CAS  PubMed  Google Scholar 

  58. Gaya JM, Palou J, Algaba F, Arce J, Rodríguez-Faba OVH. The case for conservative management in the treatment of patients with non-muscle-invasive micropapillary bladder carcinoma without carcinoma in situ. Can J Urol. 2010;17:5370–6.

    PubMed  Google Scholar 

  59. Samaratunga H, Khoo K. Micropapillary variant of urothelial carcinoma of the urinary bladder; a clinicopatholigical and immunohistochemical study. Histopathology. 2004;45:55–64.

    Article  CAS  PubMed  Google Scholar 

  60. Willis DL, Fernandez MI, Dickstein RJ, et al. Clinical outcomes of cT1 micropapillary bladder cancer. J Urol. 2015;193:1129–34.

    Article  PubMed  Google Scholar 

  61. Abufaraj M, Foerster B, Schernhammer E, Moschini M, Kimura S, Hassler MR, Preston MA, Karakiewicz PI, Remzi M, Shariat SF. Micropapillary urothelial carcinoma of the bladder: a systematic review and meta-analysis of disease characteristics and treatment outcomes. Eur Urol. 2018:1–10.

    Google Scholar 

  62. Chang SS, Bochner BH, Chou R, et al. Treatment of non-metastatic muscle-invasive bladder cancer: AUA/ASCO/ASTRO/SUO guideline. J Urol. 2017;198:552–9.

    Article  PubMed  PubMed Central  Google Scholar 

  63. Alfred Witjes J, Lebret T, Compérat EM, et al. Updated 2016 EAU guidelines on muscle-invasive and metastatic bladder cancer. Eur Urol. 2017;71:462–75.

    Article  CAS  PubMed  Google Scholar 

  64. Grossman HB, Natale RB, Tangen CM, et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med. 2003;349:859–66.

    Article  CAS  PubMed  Google Scholar 

  65. Culp SH, Dickstein RJ, Grossman HB, et al. Refining patient selection for neoadjuvant chemotherapy before radical cystectomy. J Urol. 2014;191:40–7.

    Article  PubMed  Google Scholar 

  66. Moschini M, Soria F, Klatte T, et al. Validation of preoperative risk grouping of the selection of patients Most likely to benefit from neoadjuvant chemotherapy before radical cystectomy. Clin Genitourin Cancer. 2017;15:e267–73.

    Article  PubMed  Google Scholar 

  67. Pokuri VK, Syed JR, Yang Z, et al. Predictors of complete pathologic response (pT0) to neoadjuvant chemotherapy in muscle-invasive bladder carcinoma. Clin Genitourin Cancer. 2016;14:e59–65.

    Article  PubMed  Google Scholar 

  68. Scosyrev E, Ely BW, Messing EM, et al. Benefit from neoadjuvant platinum-based locally advanced bladder cancer ? A secondary analysis of southwest oncology group-directed intergroup study (S8710). BJU Int. 2010;108:693–700.

    PubMed  PubMed Central  Google Scholar 

  69. El Mawla NG, Mansour MA, Eissa S, Ali NM, Elattar I, Hamza MR, Khaled H, Habboubi N, Elsebai I. A randomized pilot study of high-dose epirubicin as neoadjuvant chemotherapy in the treatment of cancer of the bilharzial bladder. Ann Oncol. 1991;2:137–40.

    Article  Google Scholar 

  70. Kassouf W, Spiess PE, Siefker-Radtke A, Swanson D, Grossman HB, Kamat AM, Munsell MF, Guo CC, Czerniak BA, Dinney CP. Outcome and patterns of recurrence of nonbilharzial pure squamous cell carcinoma of the bladder: a contemporary review of the university of Texas M. D Anderson cancer center experience. Cancer. 2007;110:764–9.

    Article  PubMed  Google Scholar 

  71. Yu B, Zhou J, Cai H, Xu T, Xu Z, Zou Q, Gu M. Neoadjuvant chemotherapy for primary adenocarcinomas of the urinary bladder: a single-site experience. BMC Urol. 2015;15:4–7.

    Article  CAS  Google Scholar 

  72. Vetterlein MW, Wankowicz SAM, Seisen T, et al. Neoadjuvant chemotherapy prior to radical cystectomy for muscle-invasive bladder cancer with variant histology. Cancer. 2017;123:4346–55.

    Article  CAS  PubMed  Google Scholar 

  73. Siefker-Radtke AO, Kamat AM, Grossman HB, Williams DL, Qiao W, Thall PF, Dinney CP, Millikan RE. Phase II clinical trial of neoadjuvant alternating doublet chemotherapy with ifosfamide/doxorubicin and etoposide/cisplatin in small-cell urothelial cancer. J Clin Oncol. 2009;27:2592–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  74. Kamat AM, Dinney CPN, Gee JR, Grossman HB, Siefker-Radtke AO, Tamboli P, Detry MA, Robinson TL, Pisters LL. Micropapillary bladder cancer: a review of the University of Texas M. D. Anderson Cancer center experience with 100 consecutive patients. Cancer. 2007;110:62–7.

    Article  PubMed  Google Scholar 

  75. Joshi S, Handorf E, Correa A, et al. Systemic therapy and overall survival trends in patients with non-urothelial histologic variants of muscle invasive bladder cancer undergoing radical cystectomy. J Clin Oncol. 2017;35:376.

    Article  Google Scholar 

  76. McConkey DJ, Grossman HB, Guo CC, et al. Clinical risk stratification in patients with surgically resectable micropapillary bladder cancer. BJU Int. 2016;119:684–91.

    PubMed  Google Scholar 

  77. Spiess PE, Tuziak T, Tibbs RF, Bassett R, Tamboli P, Brown GA, Grossman HB, Ayala AG, Czerniak B. Pseudosarcomatous and sarcomatous proliferations of the bladder. Hum Pathol. 2007;38:753–61.

    Article  CAS  PubMed  Google Scholar 

  78. Wang J, Wang FW, Lagrange CA, Hemstreet GP, Kessinger A. Clinical features of sarcomatoid carcinoma (carcinosarcoma) of the urinary bladder: analysis of 221 cases. Sarcoma. 2010. https://doi.org/10.1155/2010/454792.

  79. Linder BJ, Frank I, Cheville JC, Thompson RH, Thapa P, Tarrell RF, Boorjian SA. Outcomes following radical cystectomy for nested variant of urothelial carcinoma: a matched cohort analysis. J Urol. 2013;189:1670–5.

    Article  PubMed  Google Scholar 

  80. Moschini M, Dell’Oglio P, Luciano R, et al. Incidence and effect of variant histology on oncological outcomes in patients with bladder cancer treated with radical cystectomy. Urol Oncol Semin Orig Investig. 2017;35:335–41.

    Google Scholar 

  81. Fairey AS, Daneshmand S, Wang L, Schuckman A, Lieskovsky G, Djaladat H, Cai J, Miranda G, Skinner EC. Impact of micropapillary urothelial carcinoma variant histology on survival after radical cystectomy. Urol Oncol Semin Orig Investig. 2014;32:110–6.

    Google Scholar 

  82. Xylinas E, Rink M, Robinson BD, et al. Impact of histological variants on oncological outcomes of patients with urothelial carcinoma of the bladder treated with radical cystectomy. Eur J Cancer. 2013;49:1889–97.

    Article  PubMed  Google Scholar 

  83. Choong NWW, Quevedo JF, Kaur JS. Small cell carcinoma of the urinary bladder: the mayo clinic experience. Cancer. 2005;103:1172–8.

    Article  PubMed  Google Scholar 

  84. Kaushik D, Frank I, Boorjian SA, Cheville JC, Eisenberg MS, Thapa P, Tarrell RF, Thompson RH. Long-term results of radical cystectomy and role of adjuvant chemotherapy for small cell carcinoma of the bladder. Int J Urol. 2015;22:549–54.

    Article  PubMed  Google Scholar 

  85. Patel S, Stimson C, Zaid H, Barocas D, Resnick M, Cookson M, Chang S. Small cell carcinoma of the bladder: clinical characteristics and treatment patterns. J Urol. 2013;189:e770.

    Article  CAS  Google Scholar 

  86. Siefker-Radtke AO, Dinney CP, Abrahams NA, Moran C, Shen Y, Pisters LL, Grossman HB, Swanson DA, Millikan RE. Evidence supporting preoperative chemotherapy for small cell carcinoma of the bladder: a retrospective review of the M. D Anderson cancer experience J Urol. 2004;172:481–4.

    Google Scholar 

  87. Raghavan D. POINT: is cystectomy needed for small-cell bladder cancer? Oncol (Willist Park). 2015;29:645–7.

    Google Scholar 

  88. Kollmeier M. COUNTERPOINT: is cystectomy needed for small-cell bladder Cancer? Oncol (Willist Park). 2015;29:645.

    Google Scholar 

  89. Gschwend JE, Heck MM, Lehmann J, et al. Extended versus limited lymph node dissection in bladder cancer patients undergoing radical Cystectomy: Survival Results from a Prospective, Randomized Trial. Eur Urol. 2018. https://doi.org/10.1016/j.eururo.2018.09.047.

  90. Bruins HM, Veskimae E, Hernandez V, et al. The impact of the extent of lymphadenectomy on oncologic outcomes in patients undergoing radical cystectomy for bladder cancer: a systematic review. Eur Urol. 2014;66:1065–77.

    Article  PubMed  Google Scholar 

  91. Reisinger SA, Mohiuddin M, Mulholland SG. Combined pre- and postoperative adjuvant radiation therapy for bladder cancer-a ten year experience. Int J Radiat Oncol Biol Phys. 1992;24:463–8.

    Article  CAS  PubMed  Google Scholar 

  92. Moschini M, Shariat SF, Abufaraj M, et al. Predicting local failure after radical cystectomy in patients with bladder cancer: implications for the selection of candidates at adjuvant radiation therapy. Urol Oncol Semin Orig Investig. 2017;35:672.e1–6.

    Google Scholar 

  93. Lohrisch C, Murray N, Pickles T, Sullivan L. Small cell carcinoma of the bladder: long term outcome with integrated chemoradiation. Cancer. 1999;86:2346–52.

    Article  CAS  PubMed  Google Scholar 

  94. Mattes MD, Kan C-C, Dalbagni G, Zelefsky MJ, Kollmeier MA. External beam radiation therapy for small cell carcinoma of the urinary bladder. Pract Radiat Oncol. 2015;5:e17–22.

    Article  PubMed  Google Scholar 

  95. Bryant CM, Dang LH, Stechmiller BK, Gilbert SM, Morris CG, Zlotecki RA. Treatment of small cell carcinoma of the bladder with chemotherapy and radiation after transurethral resection of a bladder tumor. Am J Clin Oncol. 2016;39:69–75.

    Article  CAS  PubMed  Google Scholar 

  96. Zaghloul MS, Awwad HK, Soliman O, Omar S, El Badawy S, Barsoum M, Mocktar N, Amer F. Postoperative radiotherapy of carcinoma in bilharzial bladder using a three-fractions per day regimen. Radiother Oncol. 1986;6:257–65.

    Article  CAS  PubMed  Google Scholar 

  97. Zaghloul MS, Awwad HK, Akoush HH, Omar S, Soliman O, El Attar I. Postoperative radiotherapy of carcinoma in bilharzial bladder: improved disease free survival through improving local control. Int J Radiat Oncol Biol Phys. 1992;23:511–7.

    Article  CAS  PubMed  Google Scholar 

  98. Chua KLM, Kusumawidjaja G, Murgic J, Chua MLK. Adjuvant treatment following radical cystectomy for muscle-invasive urothelial carcinoma and variant histologies: is there a role for radiotherapy? ESMO Open. 2016. https://doi.org/10.1136/esmoopen-2016-000123.

  99. Arcangeli G, Strigari L, Arcangeli S. Radical cystectomy versus organ-sparing trimodality treatment in muscle-invasive bladder cancer: a systematic review of clinical trials. Crit Rev Oncol Hematol. 2015;95:387–96.

    Article  CAS  PubMed  Google Scholar 

  100. Krasnow RE, Drumm M, Roberts HJ, et al. Clinical outcomes of patients with histologic variants of urothelial cancer treated with trimodality bladder-sparing therapy. Eur Urol. 2017;72:54–60.

    Article  PubMed  Google Scholar 

  101. Bertz S, Wach S, Taubert H, et al. Micropapillary morphology is an indicator of poor prognosis in patients with urothelial carcinoma treated with transurethral resection and radiochemotherapy. Virchows Arch. 2016;469:339–44.

    Article  CAS  PubMed  Google Scholar 

  102. Vlachostergios PJ, Jakubowski C, Tagawa ST. Trimodality therapy in variant urothelial carcinoma: choose wisely. Transl Androl Urol. 2017;6:322–5.

    Article  PubMed  PubMed Central  Google Scholar 

  103. Black PC, Brown GA, Dinney CPN. The impact of variant histology on the outcome of bladder cancer treated with curative intent. Urol Oncol. 2009;27:3–7.

    Article  PubMed  Google Scholar 

  104. Rogers CG, Palapattu GS, Shariat SF, et al. Clinical outcomes following radical cystectomy for primary nontransitional cell carcinoma of the bladder compared to transitional cell carcinoma of the bladder. J Urol. 2006;175:2048–53.

    Article  PubMed  Google Scholar 

  105. Sui W, Matulay JT, James MB, Onyeji IC, Theofanides MC, RoyChoudhury A, DeCastro GJ, Wenske S. Micropapillary bladder cancer: insights from the national cancer database. Bl Cancer. 2016;2:415–23.

    Article  PubMed  Google Scholar 

  106. Quek ML, Nichols PW, Yamzon J, Daneshmand S, Miranda G, Cai J, Groshen S, Stein JP, Skinner DG. Radical cystectomy for primary neuroendocrine tumors of the bladder: The University of Southern California experience. J Urol. 2005;174:93–6.

    Article  PubMed  Google Scholar 

  107. Lopez Beltran A, Montironi R, Cheng L. Microcystic urothelial carcinoma: morphology, immunohistochemistry and clinical behaviour. Histopathology. 2014;64:872–9.

    Article  PubMed  Google Scholar 

  108. Lopez-Beltrán A, Luque RJ, Vicioso L, Anglada F, Requena MJ, Quintero A, Montironi R. Lymphoepithelioma-like carcinoma of the urinary bladder: a clinicopathologic study of 13 cases. Virchows Arch. 2001;438:552–7.

    Article  PubMed  Google Scholar 

  109. Lopez-Beltran A, Requena MJ, Montironi R, Blanca A, Cheng L. Plasmacytoid urothelial carcinoma of the bladder. Hum Pathol. 2009;40:1023–8.

    Article  PubMed  Google Scholar 

  110. Shimada K, Nakamura M, Ishida E, Konishi N. Urothelial carcinoma with plasmacytoid variants producing both human chorionic gonadotropin and carbohydrate antigen 19-9. Urology. 2006;68:891.e7–891.e10.

    Article  Google Scholar 

  111. Kidd M, Bodei L, Modlin IM. Chromogranin a: any relevance in neuroendocrine tumors? Curr Opin Endocrinol Diabetes Obes. 2016;23:28–37.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

The authors would like to acknowledge the support of Dr. Paari Murugan, MD, who provided photomicrographs of variant tumors for use in this chapter.

Author information

Authors and Affiliations

  1. Department of Urology, University of Minnesota, Minneapolis, MN, USA

    Subodh K. Regmi

  2. Department of Urology, Rush University Medical College, Chicago, IL, USA

    Badrinath R. Konety

Authors
  1. Subodh K. Regmi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Badrinath R. Konety
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Subodh K. Regmi .

Editor information

Editors and Affiliations

  1. Department of Urology, University of Texas, MD Anderson Cancer Center, Houston, TX, USA

    Ashish M. Kamat

  2. Department of Urologic Sciences, University of British Columbia, Vancouver, BC, Canada

    Peter C. Black

Rights and permissions

Reprints and permissions

Copyright information

© 2021 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Regmi, S.K., Konety, B.R. (2021). Variant Histology: Management Pearls. In: Kamat, A.M., Black, P.C. (eds) Bladder Cancer. Springer, Cham. https://doi.org/10.1007/978-3-030-70646-3_27

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-70646-3_27

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-70645-6

  • Online ISBN: 978-3-030-70646-3

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation